Navigation Links
Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer
Date:11/5/2009

Runx2 both blocks the growth of bone cancer cells and triggers a quality control mechanism that causes abnormal cells to self-destruct. For some reason, however, Runx2 levels are dramatically reduced in bone cancer cells.

In the current study, researchers found that Bortezomib shuts down cellular machines that destroy Runx2, machines that become overactive in bone cancer patients. Bortezomib restored Runx2 levels in osteosarcoma cell lines and in osteosarcoma tumors in mice. In addition, tests found a three-fold increase in the bortezomib-treated group in the number of cancer cells testing positive for an enzyme (caspase-3) known to drive them to self-destruct. Experiments also showed that the average size of osteosarcoma tumors in bortezomib-treated mice was only 30 percent of that in the control group.

The new findings also provide the first explanation of why Runx2 levels are lower in bone cancer cells. Researchers found that Runx2, which encourages abnormal cells to self destruct, may itself become the target of cellular machines called proteosomes that break down and recycle unneeded proteins.

Specifically, the team found in osteosarcoma cells high levels of a protein called Smurf1, known to tag aging proteins for attention by protein-devouring proteosomes. The team is now looking at why levels of Smurf1 are higher in osteosarcoma. In addition, Eliseev and colleagues plan to launch a pilot study later in 2010 using bortezomib to treat osteosarcoma.

Along with Eliseev, the work was led by Yuriy Shapovalov, David Benavidez and Daniel Zuch within the Center for Musculoskeletal Research at the Medical Center. The study was funded in part by the Karen D'Amico Foundation, the James P. Wilmot Foundation and the National Institutes of Health.

"These data argue that bortezomib treatment not only caused bone cancer cells to signal fo
'/>"/>

SOURCE University of Rochester Medical Center
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solos Endoscopy, Inc.s FDA Approved MammoView(TM) Product Line to Obtain CE Mark
2. Minimally Invasive Device Approved to Treat Liver Cancer, Fibroids, Tumors, and Bleeding
3. FDA Acts to Halt Marketing of Unapproved Codeine Sulfate Tablets
4. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
5. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
6. United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
7. ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
8. Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
9. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
10. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
11. Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle ... makers of medical devices. As part of its ... in EMEA concentrates on the EMEA medical device ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8
... Aug. 25, 2011 BioRestorative Therapies, Inc. ... into a Tangible Property License Agreement with the University ... Therapies to obtain adipose (fat) tissue that will be ... ThermoStem Program , which is an adult derived ...
... ePharmaSolutions announced the successful deployment of its Enterprise ... global pharmaceutical company on more than 900 studies to ... September 2011. Clinical Trial Portals help streamline ... sites and third party vendors by providing a common ...
Cached Medicine Technology:BioRestorative Therapies Signs License Agreement With University of Utah to Obtain Adipose (Fat) Tissue for its ThermoStem Program to Treat Obesity and Metabolic Disorders 2ePharmaSolutions Announces the Deployment of its Enterprise Clinical Trial Portal for Two Global Biopharmaceutical Companies 2
(Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... NEW YORK -- The most common cause of endophthalmitis, ... trauma, eye surgery, and eye injections, are the well-known ... bacterial strains, according to a study published in the ... a review of 25 years of cases at New ... , The new study found that gram-positive bacteria, ...
(Date:8/20/2014)... HealthDay Reporter TUESDAY, Aug. 19, 2014 ... baby,s immune system is twice as common as once believed, ... This is the first evaluation of the effect of ... severe combined immunodeficiency (SCID), or "Bubble Boy" disease, the researchers ... the boy in the bubble, who was born without an ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
... similar results, , , WEDNESDAY, Feb. 25 (HealthDay News) -- If ... type of diet plan you choose. What really matters is that ... 26 issue of the New England Journal of Medicine ... of fat, protein and carbohydrates -- and found that any eating ...
... Millstone Medical Outsourcing announced today the opening of ... The company acquired the new 30,000 square foot facility ... and clean room services. The company will continue ... foreseeable future. In addition to the two Fall ...
... hormones, not HRT, researchers note , , WEDNESDAY, Feb. 25 ... help protect her from developing Parkinson,s disease, a new ... (the time from first menstruation to menopause) have a ... findings released Wednesday and scheduled to be presented at ...
... Other Health Insurers Illegally Deny Treatment to Autistic Children, ... of autistic children and their families joined Consumer Watchdog ... health insurance companies that are scheming to avoid paying ... , , Consumer Watchdog released a letter ...
... United Airlines customer service representatives, ramp employees, flight ... at Children,s Memorial Hospital and University of ... United Airlines employees today delivered teddy bears to ... and University of Chicago Comer Children,s ...
... to ,Protect the Safety Net, , WASHINGTON, Feb. 25 ... long-term care advocacy organizations, the American Health Care Association ... today praised and thanked U.S. Representatives Earl Pomeroy (D-ND), ... Brown-Waite (R-FL) for sending a new letter to President ...
Cached Medicine News:Health News:Want to Lose Weight? Just Eat Less, Diet Study Suggests 2Health News:Want to Lose Weight? Just Eat Less, Diet Study Suggests 3Health News:Millstone Medical Outsourcing Opens New Facility to Provide Additional Capacity for Advanced Inspection, Clean Room Operations 2Health News:Hormones May Help Shield Women from Parkinson's 2Health News:Parents of Autistic Children Fight Back -- Warn HMO Regulator Against Siding With Insurers Refusing to Pay for Treatment 2Health News:Parents of Autistic Children Fight Back -- Warn HMO Regulator Against Siding With Insurers Refusing to Pay for Treatment 3Health News:Delivering Bear-y Big Smiles and Millions of Miles 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 2Health News:Pomeroy, Berkley, Capito, Brown-Waite Urge Obama Administration to Protect Seniors' Care 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: